Navigation Links
EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
Date:8/7/2009

HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research and Development.

Dr. Fewell possesses more than 10 years management and scientific leadership experience in the biotechnology industry and has served at EGEN since 2003 as Director of Biology and Pharmacology. During his tenure at EGEN he has helped lead the development and testing of proprietary discovery and development initiatives contributing to a strong intellectual property position. He has been instrumental in building EGEN's research and development team and has helped foster important industry collaborations. Dr. Fewell received his Ph.D. in Biological Science from Florida State University and was a post-doctoral fellow at Cincinnati's Children Hospital. During his active career in research and development, Dr. Fewell has authored numerous scientific publications and is a named inventor on several patents and patent applications in the area of non-viral gene and siRNA delivery.

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit http://www.egeninc.com/ .


'/>"/>
SOURCE EGEN, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
2. AOBO Announces New Product Launch
3. Prix Galien USA Announces 2009 Final Candidates
4. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
5. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
6. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
7. Telik Announces Second Quarter 2009 Financial Results
8. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
9. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
10. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
11. Oncothyreon announces webcast of second quarter 2009 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:8/15/2017)... LLC , a medical device company focused on improving the safety ... ISO 13485 Certification, the global standard for medical device quality management ... ... for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates our ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
Breaking Biology News(10 mins):